『Beta Finch - Stryker - SYK - EN』のカバーアート

Beta Finch - Stryker - SYK - EN

Beta Finch - Stryker - SYK - EN

著者： Beta Finch
無料で聴く

AI-powered earnings call analysis for Stryker (SYK). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Stryker Q2 2026 Earnings Analysis

    Stryker Q2 2026 Earnings Analysis
    2026/07/31
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Stryker's Q2 2026 results — and this is a good one, because it's really a comeback story.

    But first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Okay, so context matters a lot here. Stryker got hit by a cybersecurity incident that knocked out manufacturing for about a month in Q1. So Q2 is really the "how fast can they recover" quarter.

    ALEX: And the answer is — pretty fast. Organic sales growth of 9%, adjusted EPS of $3.69, up almost 18% year over year. For a $25 billion company that had plants offline for weeks, that's a strong number.

    JORDAN: Right, CEO Kevin Lobo actually said it himself on the call — growing around 9% "given that we were knocked out for almost an entire month" is a pretty good outcome. And you saw strength pretty much everywhere: MedSurg and Neurotechnology up over 9%, Orthopedics up 8.6%. U.S. trauma and extremities grew over 12%, medical devices — Sage, Emergency Care — grew north of 13%.

    ALEX: The one soft spot was peripheral vascular, down almost 7% in the U.S. There was a supply disruption at one of their Inari manufacturing plants that caused a real backorder problem. They actually had to ration product to their best customers.

    JORDAN: Which is a rough thing to say out loud on an earnings call, but at least it's honest. Management expects that backorder to work itself down to manageable levels by the end of Q3, and they're still bullish long-term on that business — especially with the AVS acquisition that just closed, which adds an IVL, intravascular lithotripsy, product to the portfolio.

    ALEX: Let's talk strategy for a second, because there were some real headline moments here. Mako, their robotics platform, just turned 20 years old, and they had their best-ever second quarter for Mako installations, both in the U.S. and internationally. Over 2.5 million procedures done globally now, systems in 47 countries.

    JORDAN: And the bigger story is the full commercial launch of Mako RPS — that's their handheld robotics system. It's aimed at surgeons who aren't ready to commit to a full Mako cart, especially in ambulatory surgery centers doing total knees. Lobo said the haptic feedback is what's really wowing surgeons — that you can get that kind of precision in a handheld device.

    ALEX: They're also rolling out Triathlon Gold, a new insert for their knee system, a new total ankle replacement called Encompass, and a trauma plating system called Pangaea that's launching in Europe. So despite the manufacturing hit, the product pipeline didn't really slow down.

    JORDAN: Now, the money question everyone on the call kept circling back to — capital equipment. Stryker's sitting on an elevated order backlog because demand outpaced their ability to produce during the recovery. Beds, in particular — their ProCuity hospital bed business — has huge order volume they just haven't been able to fill yet.

    ALEX: And management's plan is straightforward: add manufacturing shifts and grind through the backlog in the second half of the year. Lobo was pretty confident about this, saying these aren't new products, this is stuff they know how to make — it's purely an execution and capacity question, not a demand question.

    JORDAN: That came up a lot in the Q&A, actually — analysts pushing hard on whether Stryker can really hit an implied 11% organic growth rate in the back half to reach their guidance midpoint. Lobo's response was basically, "we raised the low end of our guidance from 8% to 8.3%, that alone should tell you how confident we are."

    ALEX: On guidance — they narrowed the full-year range. O

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Stryker Q1 2026 Earnings Analysis

    Stryker Q1 2026 Earnings Analysis
    2026/05/01
    **Beta Finch Podcast Script - Stryker Q1 2026 Earnings**

    ---

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're diving into Stryker's Q1 2026 results, and wow, this was definitely not your typical earnings call.

    **ALEX:** Before we get into it, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Absolutely. So Alex, let's start with the elephant in the room - Stryker got hit by a cyberattack late in Q1. How bad was the damage?

    **ALEX:** It was significant, Jordan. Organic sales growth came in at just 2.4% - way below what you'd normally expect from Stryker. Even more telling, adjusted earnings per share dropped 8.5% to $2.60. CEO Kevin Lobo mentioned they had 40,000 laptops wiped and were essentially shut down for about three weeks.

    **JORDAN:** That's brutal. But here's what caught my attention - despite all this chaos, they maintained their full-year guidance. That's either incredibly optimistic or they have serious confidence in their recovery plan.

    **ALEX:** I'm leaning toward confidence. CFO Preston Wells was pretty detailed about why they think they'll bounce back. He explained that different business units were affected differently based on their operating models. For example, their orthopedic business has a lot of consigned inventory sitting right at hospitals, so surgeries could continue even when Stryker's systems were down.

    **JORDAN:** Right, it was more of a revenue recognition issue there rather than lost procedures. But their capital equipment business - things like hospital beds and defibrillators - that's where they really got hit because those are made-to-order products.

    **ALEX:** Exactly. And Wells said most of that lost production will shift to Q3 and Q4 rather than Q2, which makes sense given manufacturing lead times. What I found interesting was how resilient their underlying business seems to be.

    **JORDAN:** Talk about that resilience - what are the bright spots?

    **ALEX:** Well, they had their best-ever Q1 for Mako robot installations, both in the US and internationally. That's their surgical robotics platform, and utilization rates are climbing. Plus they just got European approval for Pangaea - that's their trauma plating system that's been driving explosive growth in the US.

    **JORDAN:** And let's not forget the M&A activity. They announced they're acquiring Amplitude Vascular Systems, which gets them into the intravascular lithotripsy space. That's basically using sound waves to break up calcified plaque in blood vessels.

    **ALEX:** Kevin Lobo was really bullish on that deal during the Q&A. He said it fits perfectly with their existing peripheral vascular business through Inari, which they bought last year. Same call points, same physicians.

    **JORDAN:** Speaking of the Q&A, there were some great nuggets in there. One analyst asked about competitive dynamics in orthopedics, and Lobo basically said "bring it on." He mentioned they expect to keep outgrowing the orthopedic market by 200 to 300 basis points, just like they have been.

    **ALEX:** I loved his comment about their robotics portfolio too. He said the new Mako RPS - that's their handheld robotic system - is getting great feedback, especially in ambulatory surgery centers. It's like a stepping stone for surgeons who find full Mako too intimidating.

    **JORDAN:** The international story is pretty compelling too. While the US grew 1.9%, international was up 3.9% despite the cyber issues. Lobo highlighted Japan as their second-largest market outside the US, and it's experiencing "tremendous growth."

    **ALEX:** And they're just getting

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Stryker Q4 2025 Earnings Analysis

    Stryker Q4 2025 Earnings Analysis
    2026/02/27
    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you the insights that matter. I'm Alex.

    **JORDAN**: And I'm Jordan. Today we're diving into Stryker's Q4 2025 earnings - and folks, this medical device giant just delivered what CEO Kevin Lobo called "outstanding results" across all key metrics.

    **ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN**: Absolutely. Now Alex, let's talk numbers because Stryker really brought the heat this quarter.

    **ALEX**: They sure did, Jordan. Stryker crushed it with 11% organic sales growth in Q4, hitting over $25 billion in sales for the full year. That's their fourth consecutive year of double-digit organic growth. And here's what I love - they managed 10.3% growth for the full year against a tough 10.2% comparable from 2024.

    **JORDAN**: The consistency is remarkable. And it wasn't just the top line - adjusted earnings per share jumped 11.5% to $4.47 in the quarter, with full-year EPS up 11.8% to $13.63. What really stands out to me is they achieved this while managing $400 million in tariff headwinds, including an incremental $200 million hit they're expecting in 2026.

    **ALEX**: That tariff management is impressive. Preston Wells, their CFO, mentioned they're absorbing these costs while still driving meaningful operating margin expansion. Speaking of which, they delivered their second consecutive year of at least 100 basis points of margin expansion. That shows real operational muscle.

    **JORDAN**: Let's break down the business segments because there were some real standouts. MedSurg and Neurotechnology posted 12.6% organic growth, with U.S. growth hitting 13%. The instruments business was particularly hot with 19.1% U.S. growth driven by strong capital demand.

    **ALEX**: And then there's the Mako story - which honestly feels like the star of this whole show. Jordan, they had another record quarter for Mako installations, both in the U.S. and worldwide. Their installed base now includes over 3,000 Mako systems globally.

    **JORDAN**: The Mako 4 transition has been what Lobo called "an absolute home run." Here's a stat that blew me away - over two-thirds of their knee procedures and over one-third of hip procedures in the U.S. are now performed on Mako. One surgeon even told Lobo that the new revision hip application was like a "cheat code" for difficult procedures.

    **ALEX**: That's incredible feedback. And they're not stopping there - they're expanding Mako into shoulder applications mid-year, plus they just started cases on their handheld robot called Mako RPS. This is designed for surgeons who want robotic assistance but aren't ready for the full Mako system complexity.

    **JORDAN**: The RPS launch is smart positioning. It sits between their manual instruments and full Mako systems, potentially opening up new customer segments, especially in ambulatory surgery centers. Speaking of ASCs, they mentioned hips and knees are now in the high teens percentage flowing through that channel.

    **ALEX**: Let's talk guidance because this is where Stryker shows confidence in their momentum. For 2026, they're guiding 8% to 9.5% organic sales growth and adjusted EPS of $14.90 to $15.10. That top end of the range is slightly higher than where they started 2025, which Lobo says reflects their elevated capital backlog and strong procedural outlook.

    **JORDAN**: And here's something interesting from the Q&A - when asked if 10% growth was still possible, Lobo said "certainly possible" for their fifth consecutive year of double-digit growth. The confidence seems genuine, backed by that strong order book and Mako momentum.

    **ALEX**: There were some organizational changes wo

    This episode includes AI-generated content.
    続きを読む 一部表示
    9 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません